These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7258372)

  • 1. Use of stimulant medication in treating pervasive developmental disorder.
    Sporn A; Pinsker H
    Am J Psychiatry; 1981 Jul; 138(7):997. PubMed ID: 7258372
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of stimulant medication in childhood-onset pervasive developmental disorder--a case report.
    Schmidt K
    J Dev Behav Pediatr; 1982 Dec; 3(4):244-6. PubMed ID: 7153371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network
    Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylphenidate an effective treatment for ADHD?
    McDougle CJ
    J Autism Dev Disord; 2004 Oct; 34(5):593-4. PubMed ID: 15628613
    [No Abstract]   [Full Text] [Related]  

  • 5. [Methylphenidate therapy in 141 patients with hyperkinetic disorder or with pervasive developmental disorder and hyperkinesia].
    Ishizaki A; Sugama M
    No To Hattatsu; 2001 Jul; 33(4):323-8. PubMed ID: 11494575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of medication in pervasive developmental disorders.
    Sloman L
    Psychiatr Clin North Am; 1991 Mar; 14(1):165-82. PubMed ID: 1675463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Response With Methylphenidate to ADHD-Like Symptoms in Pervasive Developmental Disorder: Does CES-1 Enzyme Gene Polymorphism Have a Role?].
    Akyol Ardıç Ü; Ercan ES; Aygüneş D; Yüce D; Durak S; Kosova B
    Turk Psikiyatri Derg; 2017; 28(2):89-94. PubMed ID: 29192941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Authors' response to Bachmann and Hoffman's comments on psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study.
    Wong IC; Hsia Y
    Psychopharmacology (Berl); 2015 Mar; 232(5):985-8. PubMed ID: 25627463
    [No Abstract]   [Full Text] [Related]  

  • 9. Aggressive behavior in patients with attention-deficit/hyperactivity disorder, conduct disorder, and pervasive developmental disorders.
    Weller EB; Rowan A; Elia J; Weller RA
    J Clin Psychiatry; 1999; 60 Suppl 15():5-11. PubMed ID: 10418807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study.
    Di Martino A; Melis G; Cianchetti C; Zuddas A
    J Child Adolesc Psychopharmacol; 2004; 14(2):207-18. PubMed ID: 15319018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders.
    Scahill L; McDougle CJ; Williams SK; Dimitropoulos A; Aman MG; McCracken JT; Tierney E; Arnold LE; Cronin P; Grados M; Ghuman J; Koenig K; Lam KS; McGough J; Posey DJ; Ritz L; Swiezy NB; Vitiello B;
    J Am Acad Child Adolesc Psychiatry; 2006 Sep; 45(9):1114-23. PubMed ID: 16926619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical assessment of the effect of switch from immediate-release to extended-release methylphenidate in 181 patients with isolated attention deficit/hyperactivity disorder (AD/HD) or AD/HD associated with pervasive developmental disorder].
    Sugama M; Ishizaki A
    No To Hattatsu; 2009 Nov; 41(6):436-41. PubMed ID: 19928542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Retrospective analysis of pervasive developmental disorder patients initially diagnosed with attention deficit/hyperactivity disorder].
    Kawatani M; Nakai A; Mayumi M; Hiratani M
    No To Hattatsu; 2009 Jan; 41(1):11-6. PubMed ID: 19172810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment options for the management of pervasive developmental disorders.
    Nash K; Carter KJ
    Int J Psychiatry Med; 2016; 51(2):201-10. PubMed ID: 27079778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures.
    Posey DJ; Aman MG; McCracken JT; Scahill L; Tierney E; Arnold LE; Vitiello B; Chuang SZ; Davies M; Ramadan Y; Witwer AN; Swiezy NB; Cronin P; Shah B; Carroll DH; Young C; Wheeler C; McDougle CJ
    Biol Psychiatry; 2007 Feb; 61(4):538-44. PubMed ID: 17276750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective open trial of guanfacine in children with pervasive developmental disorders.
    Scahill L; Aman MG; McDougle CJ; McCracken JT; Tierney E; Dziura J; Arnold LE; Posey D; Young C; Shah B; Ghuman J; Ritz L; Vitiello B
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):589-98. PubMed ID: 17069547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders.
    Stigler KA; Desmond LA; Posey DJ; Wiegand RE; McDougle CJ
    J Child Adolesc Psychopharmacol; 2004; 14(1):49-56. PubMed ID: 15142391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
    Sukhodolsky DG; Scahill L; Gadow KD; Arnold LE; Aman MG; McDougle CJ; McCracken JT; Tierney E; Williams White S; Lecavalier L; Vitiello B
    J Abnorm Child Psychol; 2008 Jan; 36(1):117-28. PubMed ID: 17674186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Helping the patient who has pervasive developmental disorder.
    Searcy E
    JAAPA; 2001 Oct; 14(10):39-41, 44-5. PubMed ID: 11715674
    [No Abstract]   [Full Text] [Related]  

  • 20. [Drug therapy for AD/HD investigation of usefulness of extended-release methylphenidate and atomoxetine from the viewpoint of persistency rate].
    Sugama M; Ishizaki A
    No To Hattatsu; 2014 Jan; 46(1):22-5. PubMed ID: 24620426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.